Cagrilintide/Semaglutide 2.4/2.4

Original price was: $84.99.Current price is: $67.99.

2.4/2.4 mg

Out of stock



Molecular Formula
Molecular Weight
Monoisotopic Mass
Polar Area
Heavy Atom Count
Hydrogen Bond Donor Count
Hydrogen Bond Acceptor Count
Rotatable Bond Count
Physical Appearance
PubChem LCSS


Isomeric SMILES
Canonical SMILES


Cagrilintide/Semaglutide are two peptides of significant interest in metabolic research, particularly for their potential benefits in obesity and type 2 diabetes management. These compounds, either alone or in combination, are being studied for their effects on weight loss, glycemic control, and overall metabolic health. Below is an overview of their benefits for research purposes in lab studies, with PubMed references.


Cagrilintide is a long-acting amylin analog. Amylin is a hormone co-secreted with insulin by the pancreas and plays a role in regulating glucose metabolism and appetite.

Key Benefits and Mechanism of Action

  1. Appetite Suppression: Cagrilintide mimics the effects of amylin, leading to reduced food intake by promoting satiety and slowing gastric emptying.
  2. Weight Loss: By reducing appetite and food intake, cagrilintide has shown significant potential in promoting weight loss.
  3. Improved Glycemic Control: Cagrilintide helps to stabilize blood glucose levels by slowing the rate at which food leaves the stomach, thereby preventing postprandial spikes in blood sugar.

Research Applications

  • Obesity: Cagrilintide is primarily researched for its potential to treat obesity by reducing caloric intake and promoting weight loss.
  • Diabetes: Its role in modulating blood glucose levels makes it a candidate for improving glycemic control in individuals with type 2 diabetes.

Key Studies and References

  1. Animal Studies: Studies on rodent models have shown that cagrilintide significantly reduces food intake and body weight.
  2. Human Trials: Clinical trials have demonstrated the efficacy of cagrilintide in reducing body weight and improving metabolic parameters in obese and diabetic patients.


Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the effects of GLP-1, a hormone involved in glucose metabolism.

Key Benefits and Mechanism of Action

  1. Enhanced Insulin Secretion: Semaglutide stimulates insulin secretion in a glucose-dependent manner, aiding in better blood sugar control.
  2. Appetite Suppression: It slows gastric emptying and promotes satiety, reducing overall food intake and supporting weight loss.
  3. Weight Loss: In addition to improving glycemic control, semaglutide has been shown to significantly reduce body weight.

Research Applications

  • Type 2 Diabetes: Semaglutide is widely studied for its efficacy in improving glycemic control in patients with type 2 diabetes.
  • Obesity: Its effects on appetite and weight make it a valuable candidate for obesity research.

Key Studies and References

  1. Animal Studies: Preclinical studies have demonstrated that semaglutide effectively lowers blood glucose levels and reduces body weight in animal models.
  2. Human Trials: Clinical trials have shown that semaglutide significantly improves glycemic control and promotes weight loss in patients with type 2 diabetes.

Combination of Cagrilintide and Semaglutide

Research is also exploring the combined use of cagrilintide and semaglutide, leveraging the complementary mechanisms of these peptides to enhance weight loss and glycemic control.

Key Benefits

  1. Synergistic Effects: The combination of these peptides has the potential to provide synergistic benefits, resulting in greater weight loss and improved metabolic outcomes compared to either agent alone.
  2. Comprehensive Metabolic Control: By targeting multiple pathways involved in appetite regulation and glucose metabolism, this combination offers a holistic approach to managing obesity and diabetes.

Research Applications

  • Obesity and Diabetes: The combination therapy is being investigated for its potential to provide superior outcomes in weight management and glycemic control.

Key Studies and References

  1. Animal Studies: Studies on animal models have demonstrated enhanced weight loss and improved metabolic profiles with the combined use of cagrilintide and semaglutide.
  2. Human Trials: Early clinical trials are exploring the safety and efficacy of the combination therapy in human subjects, showing promising results.


Cagrilintide and semaglutide are promising peptides in the field of metabolic research, offering significant benefits for the treatment of obesity and type 2 diabetes. Their individual and combined effects on appetite suppression, weight loss, and glycemic control are supported by extensive preclinical and clinical research. Continued studies will further elucidate their therapeutic potential and optimize their use in clinical settings.


Clients Testimonials

Leave A Review

BPC157 Peptide

Accurate research is our priority.

Same Day Shipping

Enjoy the convenience of receiving your order swiftly. We offer same-day shipping on all orders of in-stock items placed before 12:00 pm EST.

Dedicated Service

Our dedicated team is always at your service, Ready to assist you with any customer service requests you may have. We prioritize your satisfaction and aim to provide a seamless experience.

Free Shipping

To enhance your shopping experience, We offer free shipping on all orders totaling $175 or more. Rest assured, we've got you covered!

Purist Quality

We take pride in ensuring the utmost purity of our products. Every item we offer undergoes rigorous lab testing and is certified for the highest possible purity.

Shopping cart


No products in the cart.

Continue Shopping